Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.48 |
| ▸ | HTR3B | O95264 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 5/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624489 | 1.00 | KMT2A (0.54) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL18100420 | 0.95 | ESR1 (0.50) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL18100425 | 0.95 | MEN1 (0.48) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL11649906 | 0.89 | KMT2A (0.48) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL18100423 | 0.88 | KMT2A (0.46) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL13585512 | 0.87 | HTR3E (0.48) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL13585511 | 0.87 | HTR3E (0.48) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL11385861 | 0.85 | SLC22A2 (0.47) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL16038636 | 0.85 | ESR1 (0.44) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL16038637 | 0.85 | ESR1 (0.44) | KMT2AMEN1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604947-B2 | Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-03-28 | — | — | US | disclosed |
| EP-2484670-B1 | SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2016-07-20 | — | — | EP | disclosed |
| US-9006336-B2 | Curable polysiloxane coating composition | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2838935-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M Innovative Properties Company (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140378608-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY | 2014-12-25 | — | — | US | disclosed |
| WO-2013101477-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20120225879-A1 | SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFACAS ( CSIC) (ES) | 2012-09-06 | — | — | US | disclosed |
| EP-2484670-A1 | SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2012-08-08 | — | — | EP | disclosed |
| EP-1180107-B1 | NOVEL RUTHENIUM METAL ALKYLIDENE COMPLEXES COORDINATED WITH TRIAZOLYLIDENE LIGANDS THAT EXHIBIT HIGH OLEFIN METATHESIS ACTIVITY | CALIFORNIA INST OF TECHN (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1180107-A4 | NOVEL RUTHENIUM METAL ALKYLIDENE COMPLEXES COORDINATED WITH TRIAZOLYLIDENE LIGANDS THAT EXHIBIT HIGH OLEFIN METATHESIS ACTIVITY | CALIFORNIA INST OF TECHN (US) | 2005-01-12 | — | — | EP | disclosed |
| US-4994474-A | Hypotensive agents | SANOFI (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0302793-A2 | Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | ELF SANOFI (FR) | 1989-02-08 | — | — | EP | disclosed |
| US-4639454-A | LYMPHOID LEUKEMIA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0091790-A2 | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines | REILLY INDUSTRIES, INC. (US) | 1983-10-19 | — | — | EP | disclosed |
| US-4405790-A | FROM 3-ALKYLPYRIDINE; SODIUM ALKYLAMIDE | REILLY TAR & CHEMICAL CORP. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4353830-A | Process for the preparation of substituted amidines | GENERAL ELECTRIC COMPANY (US) | 1982-10-12 | — | — | US | disclosed |
| US-4304914-A | CARDIOTONIC AGENTS, HYPOTENSIVE AGENTS | USV PHARMACEUTICAL CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-4302591-A | 1-BENZIMIDOYL-DIHYDROPYRIDINES | USV PHARMACEUTICAL CORPORATION (US) | 1981-11-24 | — | — | US | disclosed |
| US-4264505-A | ANTIARRHYTHMIA AGENTS | USV PHARMACEUTICAL CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| US-4210551-A | IMIDOYL COMPOUND AS ACTIVATOR | FMC CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225879-A1 | SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES | PDE7B, PDE7A, PARK7 | KMT2A 3709/4885MEN1 2152/4885HTR3E 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.